title: Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model.
abstract: Oral administration of celecoxib (Clx), which is the traditional treatment for osteoarthritis (OA), is accompanied by a high risk for cardiovascular events, while intra-articular injection of hyaluronate (HA) is a well-documented treatment for knee OA. To improve OA therapy while reducing the adverse effects, we formulate Clx-loaded liposomes embedded in HA gel, then administer the liposomal Clx-HA combination via intra-articular injection. Clx-loaded liposomes showed high efficiency encapsulation (>99%). In vitro release studies demonstrated that the release of Clx from lipsosomes was delayed by the combination of HA with liposomes. We examined the effect of intra-articular injection of liposomal Clx-HA combination on cartilage degeneration in rabbit knee OA model. The rabbits were treated with a single intra-articular injection of a single drug, either Clx liposome or HA, or liposomal Clx-HA combination. Using an incapacitance tester and the histopathological study, it was verified that the liposomal Clx-HA combination was more effective than a single drug in pain control and cartilage protection.
authors.affiliation: Department of Clinical Pharmacology Research Lab, the First Affiliated Hospital of Soochow University, 188 Shi Zhi Street, Suzhou 215006, China.
authors.forename: Ji
authors.initials: J
authors.lastname: Dong
authors.forename: Dinghua
authors.initials: D
authors.lastname: Jiang
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.forename: Guizhong
authors.initials: G
authors.lastname: Wu
authors.forename: Liyan
authors.initials: L
authors.lastname: Miao
authors.forename: Lixin
authors.initials: L
authors.lastname: Huang
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D002358:Cartilage, Articular / Q000187:drug effects / Q000473:pathology; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D005782:Gels; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D007270:Injections, Intra-Articular; D008081:Liposomes; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D055675:Viscosupplements / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D005782:Gels; D008081:Liposomes; D011720:Pyrazoles; D013449:Sulfonamides; D055675:Viscosupplements; D006820:Hyaluronic Acid; D000068579:Celecoxib